Clinical Trial Update: Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) [Phase 3]

View source ↗

Summary

This ongoing Phase 3 study assesses the long-term safety of dupilumab in children aged 6 months to under 18 years with atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Atopic Dermatitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING